Status:

COMPLETED

Prospective Evaluation of the StatusFirst™ CHF NT-proBNP Device in Human Whole Blood and Plasma Samples

Lead Sponsor:

Nanogen, Inc.

Conditions:

Congestive Heart Failure (CHF)

Eligibility:

All Genders

45+ years

Brief Summary

The primary objective of the study is to establish the correlation between NT-proBNP measurements in fresh human whole blood samples and those in plasma samples from the same study subjects, where sai...

Eligibility Criteria

Inclusion

  • Have clinically confirmed heart failure (NYHA class I-IV) or have presented to an emergency room or clinic with signs, symptoms and/or risk factors suggestive of heart failure, OR
  • Be non-CHF controls greater than 45 years of age with no history of heart failure or cardiovascular disease.

Exclusion

  • Be 45 years of age or younger

Key Trial Info

Start Date :

February 1 2008

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

November 1 2008

Estimated Enrollment :

450 Patients enrolled

Trial Details

Trial ID

NCT00734045

Start Date

February 1 2008

End Date

November 1 2008

Last Update

December 10 2008

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

US Department of Veteran's Affairs

San Diego, California, United States, 92161

2

San Francisco General Hospital

San Francisco, California, United States, 94110

Prospective Evaluation of the StatusFirst™ CHF NT-proBNP Device in Human Whole Blood and Plasma Samples | DecenTrialz